Coverage
-
June 06, 2014
The Third Circuit refused Friday to revive a class of Pfizer Inc. shareholders' securities fraud suit accusing its executives of making false statements over clinical trial data related to the development of an experimental Alzheimer's drug, ruling the complaint failed to state a claim.
1 other articles on this case.
View all »